KCM
ORMP icon

Knoll Capital Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Knoll Capital Management’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-20,000
Closed -$130K – 32
2022
Q3 		$130K Hold
20,000
– – 0.08% 32
2022
Q2 		$92K Hold
20,000
– – 0.05% 38
2022
Q1 		$173K Buy
+20,000
New +$205K 0.11% 39

Other funds holding ORMP

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
LC
Lindbrook Capital Calabasas, California $1.08B AUM 10.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Knoll Capital Management's ORMP Position: Q4 2022 in Review

Knoll Capital Management sold out of Oramed Pharmaceuticals (ORMP) in Q4 2022, closing a stake of 20,000 shares — an estimated $130K sold.

Knoll Capital Management first reported a position in ORMP in Q1 2022 and held it in 3 quarters. The position peaked at $173K in Q1 2022. 77 funds tracked by Wall St. Rank hold ORMP as of Q4 2022.

  • Knoll Capital Management reported no remaining Oramed Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Knoll Capital Management sold 20,000 Oramed Pharmaceuticals shares in Q4 2022, an estimated $130K.
  • Knoll Capital Management first reported a position in Oramed Pharmaceuticals in Q1 2022 and held it in 3 quarters.
  • Knoll Capital Management's Oramed Pharmaceuticals position peaked at $173K in Q1 2022.
  • 77 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q4 2022.

Based on Knoll Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.